Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab
详细信息 查看全文
- 作者：Benoî ; t Dupont ; Delphine Mariotte ; Audrey E. Dugué ; Bé ; né ; dicte Clarisse ; Jean-Michel Grellard ; Emmanuel Babin ; Bruno Chauffert ; Sté ; phanie Dakpé ; Cristian Moldovan ; Karine Bouhier-Leporrier ; Jean-Marie Reimund ; Frederic Di Fiore ; Sylvie Zanetta ; Audrey Mailliez ; Pascal Do ; Annie Peytier ; Marie-Pierre Galais ; Carmen Florescu ; Roland Schott ; Brigitte Le Mauff and Radj Gervais
- 刊名：British Journal of Clinical Pharmacology
- 出版年：2017
- 出版时间：March 2017
- 年：2017
- 卷：83
- 期：3
- 页码：623-631
- 全文大小：520K
- ISSN：1365-2125
文摘
Cetuximab is an anti-epidermal growth factor receptor antibody used for the treatment of metastatic colorectal cancer and head and neck cancer. Hypersensitivity reactions (HSRs) are associated with cetuximab use. The aim of the study was to evaluate the utility of anti-cetuximab immunoglobulin E (IgE) detection in order to identify patients at risk of HSR to cetuximab.